StockNow
Log in
U.S. Markets

Eli Lilly (LLY) confirms that 2 phase 3 trials evaluating Retatrutide met the primary endpoint and plans for BLA submission in Q1'27

StockNow breaking-news AI analysis

Eli Lilly confirmed two successful Phase 3 Retatrutide trials and plans a Q1 2027 BLA submission. The drug showed up to 30.3% weight loss in earlier TRIUMPH-1 data.

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

Geopolitics

The draft agreed to by Iranian and Omani negotiators awaits final approval from Iran’s supreme leader, two regional officials told The Associated Press on Wednesday

Geopolitics

Only 'one or two issues' remain unresolved in Iran-Oman talks, a senior diplomatic source tells Al Jazeera